The Eukaryotic Translation Initiation Factor 4E (eIF4E) as a Therapeutic Target for Cancer | Zendy

Sara Karaki | Zendy; Claudia Andrieu | Zendy; Hajer Ziouziou | Zendy; Palma Rocchi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Eukaryotic Translation Initiation Factor 4E (eIF4E) as a Therapeutic Target for Cancer

Author(s) -

Sara Karaki,

Claudia Andrieu,

Hajer Ziouziou,

Palma Rocchi

Publication year - 2015

Publication title -

advances in protein chemistry and structural biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.262

H-Index - 72

eISSN - 1876-1631

pISSN - 1876-1623

DOI - 10.1016/bs.apcsb.2015.09.001

Subject(s) - eif4e , translation (biology) , eukaryotic translation , initiation factor , eif4a1 , cancer , eukaryotic initiation factor , cancer research , biology , computational biology , microbiology and biotechnology , messenger rna , genetics , gene

Cancer cells depend on cap-dependent translation more than normal tissue. This explains the emergence of proteins involved in the cap-dependent translation as targets for potential anticancer drugs. Cap-dependent translation starts when eIF4E binds to mRNA cap domain. This review will present eIF4E's structure and functions. It will also expose the use of eIF4E as a therapeutic target in cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research